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Abstract. We evaluated the relationship between motor and neuropsychological deficits in subjects affected by amnestic Mild
Cognitive Impairment (aMCI) and early Alzheimer’s Disease (AD). Kinematics of goal-directed movement of aMCI and AD
subjects were compared to those of age-matched control subjects. AD showed a slowing down of motor performance compared
to aMCI and controls. No relationships were found between motor and cognitive performances in both AD and aMCI. Our
results suggest that the different motor behaviour between AD and aMCI cannot be related to memory deficits, probably reflecting
the initial degeneration of parietal-frontal circuits for movement planning. The onset of motor dysfunction in early AD could
represent the transition from aMCI to AD.
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1. Introduction
Alzheimer disease (AD) is the most common form of
dementia, accounting for 50% to 70% of all cases [17].
Multiple cognitive deficits and functional impairment
are the main features of dementia and AD, characteriz-
ing the diagnostic criteria currently used [3,29]. How-
ever, because of worse prognosis, other symptoms such
neuropsychiatric abnormalities [4] and motor impair-
ment [14] have to be considered. AD pathology ex-
ists covertly over a period of months to years before
the onset of clinically detectable symptoms [11]; the
early recognition of subtle cognitive impairment due to
the disease from cognitive changes of normal aging is
sometimes not easy.
In the last years, the status of subtle cognitive im-
pairment in nondemented elderly has attracted intense
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interest. Within the different syndromes with vari-
able prognosis proposed [13] the construct of Mild
Cognitive Impairment (MCI) [39] has been one of the
most commonly investigated. According to Petersen et
al. [39] original definition, the term MCI refers to in-
dividuals with subjective memory complaint, impaired
memory testing, normal general cognitive functioning
and relatively intact activities of daily living. These
criteria basically centered on impaired memory, the so-
called amnestic Mild Cognitive Impairment (aMCI),
have been broadened recently to encompass other non-
memory cognitive domains with a subsequent descrip-
tion of other MCI subtypes [40]. Subjects with aMCI
show an high rate of progression to AD with an annual
conversion rate of about 12% vs 1–2% in cognitively
intact elderly [39].
As well as for cognitive functioning, a continuum
regarding age-related changes and disability due to
Alzheimer’s disease may be hypothesized also for mo-
tor functions since abnormalities in these functions in-
crease in frequency and severity over time coupling the
ongoing decline of cognitive functions [46,50]. The
clinical examination of AD patients often shows sever-
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al types of extrapyramidal signs (EPS) [46,50]. EPS in
AD increase in prevalence as the disease advances [46,
50] and are associated with cognitive and functional de-
cline [46,50], institutionalization [46], increased costs
of care [32] and death [46]. EPS in AD are associated
with substantia nigra pathology although causative le-
sions for EPS outside the extrapyramidal system cannot
be excluded [8].
Recent population-based cohort studies showed that
motor function is impaired in subjects with MCI [1,
27] and that the degree of EPS in lower extremity is
related to the risk of AD [1]. By contrast, in a clinical-
based study, the assessment of motor function with
performance-based tests failed to show any impairment
in MCI subjects [42].
Very few studies to date have applied quantitative in-
strumental methods to evaluate motor functions in cog-
nitively impaired elderly subjects [20,21,23,47]. Us-
ing these methods, slight motor dysfunctions have been
found in the early stage of AD [20,21,23], probably
accounting for memory impairment. These data were
recently confirmed by a German kinematic study con-
ducted in aMCI subjects,who showed loss of fine motor
performance compared to healthy controls [47]. How-
ever, in this article the authors did not controlled for
coexistent depression and extrapyramidal motor signs,
all factors that may have interfered with motor perfor-
mances.
According to previous findings it is not clear whether
in cognitively impaired elderly motor failure matches
the decline of memory function or alternatively is cou-
pled with the decline of other cognitive functions than
memory. To address this issue, using a visuomotor
integration task, we studied the kinematics of the up-
per limb of a group of subjects with mild-to-moderate
AD and compared them with the kinematics of a group
of subjects with aMCI. Motor performance of both
groups were then related to neuropsychological scores
obtained in cognitive tasks. To control for confounding
we excluded subjects with mild to severe EPS, depres-
sive symptoms or under psychotropic medications.
2. Materials and methods
2.1. Subjects
Eleven patients with AD (6 women and 5 men), 11
with aMCI (6 women and 5 men) and 11 healthy con-
trols (6 women and 5 men) participated to the study.
Diagnostic evaluation of AD and aMCI patients in-
cluded physical and neurological evaluation, neuropsy-
chological testing, laboratory testing, and neuroimag-
ing with brain computed tomography or magnetic res-
onance imaging.
The diagnosis of dementia was based on the Diag-
nostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV-TR) [3], and the diagnosis of AD was
based on the criteria of the National Institute for Neu-
rological and Communicative Disorders and Stroke-
Alzheimer Disease and Related Disorders Association
(NINCDS-ADRDA) [29]. Only mild-to-moderate AD
subjects were included (i.e. Mini-Mental State Exami-
nation [MMSE] [16] scores ranged from 17 to 24).
Subjects with aMCI were ascertained according to
the criteria proposed by Petersen et al. [39], including:
(a) memory complaints reported by the subject or the
informant (or both); (b) objective memory impairment
for age and education (1.5 SD below the age- and ed-
ucation adjusted scores); (c) normal global cognitive
function (MMSE score > 24); (d) intact activities of
daily living (Activities of Daily Living [ADL] score =
6/6) [26]; (e) Clinical Dementia Rating (CDR) score
of 0.5 [31]; (f) absence of dementia (DSM-IV-TR cri-
teria) [3]. Neither aMCI nor AD subjects were on
psychotropic medications (i.e. neuroleptics, anxyoli-
tics including benzodiazepines other tranquilizers and
hypnotic, and antidepressants) or experienced depres-
sive symptoms (i.e. Cornell Depression Scale score
 7) [2].
Controls were matched for gender, age and educa-
tion to aMCI and AD subjects. Inclusion criteria were:
(a) no diagnosis of major medical, neurological or psy-
chiatric illness; (b) no history of significant head injury
or substance abuse; (c) no evidence of dementia, func-
tional (ADL = 6/6) or cognitive decline (MMSE > 27)
on examination.
For all subjects common inclusion criteria were: (a)
the absence of any kind of tremor in upper extremities
and the presence of mild-to-absent EPS (i.e. a score <
7 at the Motor Examination of the Unified Parkinson’s
Disease Rating Scale [UPDRS-ME] [15]); (b) being
right-handed according to the Edinburgh Inventory of
handedness [35].
All subjects gave their informed consent prior to their
inclusion to the study, which was approved by the local
Ethical Board.
2.2. Neuropsychological evaluation
The neuropsychological battery included tests of
verbal long-term memory (Rey’s Word List Learning
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Immediate and 10 min Delayed Recall) [10], verbal
and spatial short-term memory (Digit Span and Cor-
si Span) [36], constructional abilities (Copy Drawings
with and without Landmarks) [18], attention and psy-
chomotor speed (Attentive Matrices and Trial Mak-
ing Test part A, TMT-A) [22,49], non-verbal reason-
ing (Raven Coloured Matrices) [6], auditory language
comprehension (Token Test) [12] and executive func-
tions (Verbal Fluency test with phonemic cues) [34].
Tests were administered by an experienced examiner
blind to results of the kinematic session and scored ac-
cording to the age- and education published procedures
for the Italian population [6,10,12,18,22,34,36,49].
2.3. Kinematic evaluation
A visuomotor integration task was executed in a sep-
arate session, run at least one day apart from the neu-
ropsychological testing. Subjects sat in front of a table
placing their right index finger on the starting position
(SP) located on the table’s plane, 7 cm from its edge.
Six flat LEDs were placed on the table’s surface that
was inclined 10 degrees on the horizontal plane. LEDs
were located at two distances from SP (15 and 30 cm)
along three axes (midsagittal, right and left directions,
oriented 0◦, 60◦ to the right and 60◦ to the left with
respect to the subject’s midline, respectively). Subjects
were required to point and touch with the right index
finger the LED that was turned on, with their maximal
velocity and accuracy. Order of target presentation was
randomly assigned by the computer controlling the ap-
paratus and the device for the motion analysis. Po-
sition of final target was varied in order to avoid any
habituation effect. Movements were recorded by using
the ELITE optoelectronic system (BTS, Milan, Italy)
and consisted of two TV-cameras detecting infrared,
reflecting passive markers. Images were acquired at
the sampling rate of 100 Hz. In this study, two markers
were used. The first one was placed on the nail of the
index finger, the second one was placed on the table
and was considered as a reference point. Subjects per-
formed 42 trials in a total, that is 7 pointing movements
for each one of the 6 possible targets.
2.4. Statistical analysis
Neuropsychological performance of AD and aMCI
subjects was compared with two-tailed t-test. Concern-
ing the kinematic evaluation, for each group of sub-
jects (AD, aMCI and controls) mean values of reaction
times (RT) movement times (MT), peaks of accelera-
tion (PKA) peaks of velocity (PKV) and peaks of de-
celeration (PKD) of pointing movements were collect-
ed and analyzed. RT was the time between the switch-
on of the LED on the target and the beginning of the
movement; MT was considered as the interval between
the beginning and the end of the movement. PKA,
PKV and PKD were considered as the maximal val-
ues tangential velocity, acceleration and deceleration,
respectively. PKA and PKV were chosen to evaluate
the initial phase of the movement, MT was chosen to
evaluate the whole movement course, PKD to evaluate
the final corrective phase. Data were averaged across
movement direction and target position and compared
by means of ANOVA. The Newman-Keuls test was em-
ployed as post-hoc test. Neuropsychological perfor-
mance in aMCI and AD was related to mean kinemat-
ics (RT, MT, PKV PKA and PKD) by means of simple
linear correlation (Pearson r). For all analyses level of
significance was set at p  0.05.
3. Results
3.1. Demographics and clinical characteristics
Demographics of subjects are summarized in Ta-
ble 1. AD and aMCI subjects were significantly dif-
ferent from controls on the UPDRS-ME, while do not
differing each other (p = 0.6). As expected AD sub-
jects showed the worst MMSE score and those with
MCI performed at intermediate level between AD and
controls.
3.2. Neuropsychological performance
Table 2 shows the mean scores of the neuropsycho-
logical tests and the corresponding p-values of pair
comparisons between aMCI and AD subjects. The lat-
ter performed significantly worse than aMCI subjects
in tasks evaluating short-term visuospatial memory, vi-
suoconstructive abilities, non-verbal reasoning, atten-
tion and psychomotor speed, auditory language com-
prehension and executive functioning. AD and MCI
subjects showed similar performance in test exploring
short- and long-term verbal memory.
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Table 1
Mean demographics (± SD), MMSE and UPDRS-ME scores for sub-
jects with Alzheimer’s disease, amnestic mild cognitive impairment and
controls
AD aMCI Controls
Age, years 70.82 ± 6.37 69.73 ± 7.88 69.72 ± 9.10
Education, years 6.45 ± 4.55 10.64 ± 5.22 9.73 ± 5.35
UPDRS-ME 4.27 ± 2.00∗ 3.82 ± 2.32∗ 1.18 ± 1.25
MMSE 20.27 ± 2.65∗ 26.18 ± 1.17∗ 28.45 ± 1.13
Abbreviations: AD = Alzheimer’s disease; aMCI = amnestic mild cog-
nitive impairment; UPDRS-ME = Motor Examination of the Unified
Parkinson Disease Rating Scale; MMSE = Mini Mental State Exami-
nation.
∗p  0.05 vs controls.
Table 2
Mean neuropsychological scores (± SD) of subjects with Alzheimer’s disease and
amnestic mild cognitive impairment
Task* AD aMCI p t
Long-term memory
Rey’s Word List Learning IR 18.4 ± 7.5 23.1 ± 5.8 ns 1.60
Rey’s Word List Learning DR 2.5 ± 1.8 2.3 ± 1.3 ns 0.40
Short-term memory
Corsi Span 3.6 ± 0.9 4.4 ± 0.7 0.05 2.10
Digit Span 4.5 ± 1.0 5.1 ± 1.0 ns 1.22
Visuoconstructive Abilities
CD with landmarks 6.7 ± 2.3 8.8 ± 1.8 ns 1.57
CD without landmarks 52.8 ± 11.4 59.4 ± 7.9 0.03 2.37
Non-verbal Reasoning
Raven Coloured Matrices 15.2 ± 4.3 23.1 ± 7.0 0.001 3.40
Attention/Psychomotor Speed
Attentive Matrices 28.4 ± 7.5 39.0 ± 6.9 0.001 3.40
Trail Making A 249.5 ± 106.5 119.0 ± 33.5 0.001 3.88
Language
Token Test 24.50 ± 5.2 31.4 ± 2.5 0.001 3.89
Executive functions
Phonemic Fluency 12.27 ± 7.78 24.0 ± 9.22 0.004 3.22
∗All scores are expressed as raw scores. Abbreviations: Abbreviations: AD =
Alzheimer’s disease; aMCI = amnestic mild cognitive impairment; IR = immediate
recall; DR = delayed recall; CD = copy drawings.
3.3. Kinematic evaluation
Mean values of kinematics are reported in Table 3.
At ANOVA significant was the difference in RT among
the three groups of subjects (F (2, 30) = 5.44, p =
0.01). Figure 1 depicts the differences in mean MT
between the three groups of subjects (F (2, 30) =
18.90, p = 0.00005). Post-hoc evaluation showed that
AD were significantly different from aMCI and con-
trols (p < 0.0001) whereas no differences were found
between aMCI and controls. As well as for MT, same
differences were found for PKA (F (2, 30) = 7.18, p =
0.003), PKV (F (2, 30) = 6.81, p = 0.003) and PKD
(F (2, 30) = 6.61, p = 0.004). Post-hoc evaluation
showed again no differences between aMCI and con-
trols and a significant reduction of maximal velocity
and acceleration peaks in AD respect to the two other
groups. Only for MT significant was the 3-way interac-
tion between groups of subjects, distances and direction
of movements (F (4, 60) = 4.19, p = 0.004).
3.4. Kinematics and neuropsychological tests
correlations
There was no consistent relationship between kine-
matics and neuropsychological scores both in AD and
aMCI (data not shown).
4. Discussion
Few studies to date have evaluated whether a decline
of motor functions in AD is related to a memory de-
cline or, in alternative, to the involvement of cognitive
R. Camarda et al. / Kinematics of aMCI and AD 139
Table 3
Mean reaction times and kinematics (± SD) of subjects with Alzheimer’s disease, amnestic mild cognitive impairment and controls for each
distance and position of the employed targets
Near target Far target
Right Central Left Right Central Left
AD
RT (ms) 740.0 ± 32.8 775.3 ± 44.5 761.9 ± 42.5 815.7 ± 52.5 861.8 ± 64.4 859.8 ± 84.9
PKA (mm/s2) 7477.1 ± 849.2 8119.5 ± 937.1 7039.4 ± 690.3 10341.5 ± 1258.7 9466.8 ± 1251.4 8616.0 ± 1069.5
PKV (mm/s) 705.2 ± 34.1 593.1 ± 40.6 509.6 ± 41.3 1193.5 ± 74.8 864.8 ± 53.6 759.9 ± 43.8
PKD (mm/s2) 6422.6 ± 635.8 5179.0 ± 716.6 4924.1 ± 671.2 8561.2 ± 937.5 5409.7 ± 642.1 4622.2 ± 544.0
MT (ms) 560.1 ± 21.6 618.8 ± 26.4 660.9 ± 22.0 693.0 ± 32.8 794.3 ± 44.5 876.6 ± 40.2
aMCI
RT (ms) 599.0 ± 45.6 592.4 ± 47.3 623.5 ± 47.8 760.6 ± 94.2 751.1 ± 82.0 708.1 ± 89.4
PKA (mm/s2) 17075.4 ± 2274.3 15798.0 ± 2462.8 12405.4 ± 1695.1 20867.0 ± 2849.4 20065.1 ± 2868.7 16074.1 ± 2514.5
PKV (mm/s) 1024.1 ± 89.2 809.4 ± 64.2 706.8 ± 52.9 1550.5 ± 141.9 1180.7 ± 90.4 1047.0 ± 73.8
PKD (mm/s2) 12127.6 ± 1803.6 8744.1 ± 1008.0 8005.4 ± 1023.1 15170.1 ± 2022.1 9417.1 ± 1276.6 8127.8 ± 876.2
MT (ms) 430.6 ± 22.9 485.2 ± 22.1 545.6 ± 23.5 572.9 ± 19.4 617.2 ± 33.2 661.6 ± 30.3
Controls
RT (ms) 577.5 ± 13.5 573.6 ± 21.7 617.1 ± 22.7 630.9 ± 27.9 639.5 ± 35.8 665.8 ± 25.9
PKA (mm/s2) 13318.1 ± 1028.0 14026.1 ± 1849.6 10805.1 ± 1293.5 17734.3 ± 1657.1 17737.7 ± 2167.6 14932.0 ± 1705.8
PKV (mm/s) 931.7 ± 40.8 775.3 ± 55.5 674.7 ± 35.8 1434.2 ± 49.7 1170.2 ± 51.1 1028.4 ± 33.8
PKD (mm/s2) 9689.1 ± 945.9 8381.2 ± 877.5 7762.9 ± 706.3 11206.2 ± 882.5 9085.1 ± 882.2 8184.6 ± 669.1
MT (ms) 424.3 ± 9.1 460.2 ± 11.8 496.2 ± 11.4 531.5 ± 14.0 584.4 ± 17.3 635.4 ± 15.2
Abbreviations: AD = Alzheimer’s disease; aMCI = amnestic mild cognitive impairment; RT = Reaction Time; PKA = Peak of Acceleration;
PKV = Peak of Velocity; PKD = Peak of Deceleration; MT = Movement Time.
Fig. 1. Mean values of movement time (MT) of pointing movements for subjects with Alzheimer’s disease (AD) (filled squares, ), amnestic
mild cognitive impairment (aMCI) (empty circles, ) and controls (filled diamonds, ). For each subject data are plotted against the respective
Mini-Mental State Examination (MMSE) raw score. Note the wider interval of distribution of MT of subjects with AD respect to aMCI and
controls.
domains other than memory [20,21]. Furthermore, on-
ly one study has evaluated motor performance in non-
demented subjects with cognitive impairment by us-
ing quantitative instrumental methods such as kinemat-
ic analyses [47]. The aim of our study was to evalu-
ate motor performance in cognitively impaired subjects
(i.e. aMCI and early AD) and to relate motor function
of these subjects to cognitive performance in memory
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and nonmemory tasks.
The main result that emerges from our study is the
presence of a slight, not significant, motor dysfunc-
tion in aMCI subjects and the presence of a remarkable
slowing down of pointing in AD subjects. This slow-
ing down was distributed throughout the whole move-
ment time course affecting both the initial programma-
tive phase (indexed by RT and PKA) and the final part
of movement when corrective adjustments were made
(indexed by PKD). These data may not be accounted
for the presence of EPS since we include in the anal-
yses only subjects with mild-to-absent EPS, and dif-
ferences in UPDRS-ME scores between AD and aMCI
were negligibile. Furthermore, our results cannot be
explainable in terms of motor slowness due to coexis-
tent depression or psychotropic medications, the latter
being associated with EPS even when administered in
very low doses [9], because at the enrollment we have
excluded subjects with depressive symptoms or under
psychotropic treatment.
It is widely accepted that kinematics of goal-directed
movements reflect the features of visuomotor transfor-
mation processes for motor planning [5,19,30]. In AD
such kind of movements is disrupted being character-
ized by slowing down and inaccuracy of execution [7,
20,21]. Previous studies have shown that such features
are due to the presence of multiple re-accelerations that
segment the whole movement both in the accelerative
and in the decelerative phases [7,20,21]. These abnor-
malities have been associated with the severity of mem-
ory decline per se and secondarily with the involve-
ment of other cognitive domains [20,21]. Recently,
this hypothesis was confirmed in aMCI subjects by a
kinematic study of handwriting conducted by Schr o¨ter
et al. [47]. Indeed, the authors reported that a loss of
fine motor performance can be found in both AD and
aMCI subjects, regardless the amount of memory de-
cline. On the opposite, others have shown that AD but
not aMCI subjects have impaired motor function [42].
Our data support these findings. In fact, since in our
sample aMCI subjects were not distinguishable from
controls in the clinical evaluation of motor function
(i.e. UPDRS-ME), but shared with mild AD compara-
ble memory deficits, the compromising of motor per-
formance in mild AD may be only accounted for the
comprehensive impairment of other non-memory cog-
nitive domains. Different results between our and those
described by Schro¨ter et al. [47] could be accounted
for, as suggested by the same authors, the presence of
depressive symptoms commonly observed in subjects
with MCI [28] or coexistent EPS not controlled in their
study.
We hypothesize that the motor impairment showed
by mild AD subjects probably reflects the compro-
mising of parietal-frontal circuits for motor program-
ming [23]. Planning of aimed reaching movements
requires the transformation of spatial targets proper-
ties (i.e. position) with respect to the body of the
subjects executing the movement [25]. Visual and
proprioceptive-kinestetic informations are transformed
in a series of commands integrated in specialized cir-
cuits located in the posterior parietal cortex [25]. The
execution of a goal-directed movement depends not
only on the efficiency of planning but also on the ef-
ficient evaluation of spatial properties of targets and
consequently on the proper allocation of spatial atten-
tion [37].
It is well known that in AD the loss of memory is
linked to the early involvement of medial temporal and
hippocampal cortices whereas other cortices are com-
promised only in successive phases of the disease [41].
On the other hand, metabolic studies in subjects with
AD have shown an early pathological hypoperfusion of
the posterior parietal regions feeding the premotor ar-
eas [24,33]; these are the same areas that are concerned
with visuomotor transformation for planning of aimed
movements. According to these studies, the quasi-to-
normal motor performance observed in our aMCI sam-
ple could be due to the preserved integrity of parieto-
frontal circuits.
In our task, subjects had to choose a position among
six possible targets. Every target was visible from the
beginning and was a potential goal for the pointing,
thus they had to look at the entire apparatus in order
to identify the target that they have to point to. This
was probably obtained shifting their attention from a
primary, neutral position toward the actual target (i.e.
the led to switch-on). In other words, task required an
initial recruitment of attentive resources. The capabil-
ity to properly select motor targets, still preserved in
healthy elderly people [48] seems to be compromised
in subjects with AD probably because of a defective
disengagement of gaze from non-relevant visual cues
in favor of the impending movement target [37,38].
However, AD were slower than aMCI not only in the
initial phases (smaller PKA and PKV) but in the whole
movement (longer MT). The compromising of parieto-
frontal circuits could explain also the differences be-
tween AD and aMCI in the late phases of movement
since parietal circuits subserve not only attentive func-
tions [43–45], but also visuo-motor functions for motor
planning and movement re-programming [25].
The strengths of this study are the strict inclusion cri-
teria and the sophisticated kinematic approach to study
R. Camarda et al. / Kinematics of aMCI and AD 141
motor function. However, some methodological issues
deserve comment. First, the cross-sectional design of
our study. Motor signs may fluctuate over time and may
be not present on every examination [50]. A prospec-
tive study design would better determine the role of
motor impairment in AD or aMCI subjects. Second, we
did not find any consistent correlation between kine-
matics of AD and cognitive performance. This finding
could be explained by a lack of statistical power due
the small groups of subjects evaluated.
In summary, mild-to-moderate AD but not aMCI
is significantly associated with abnormalities of motor
function. These data support the issue that a pure mem-
ory impairment does not affect motor performance thus
suggesting that motor abnormalities probably account
for the compromising of other non-memory domains.
Because of the prognostic value of motor impairment
in AD subjects [32,46,50], our data may have rele-
vant clinical and social implication. The slowing down
of motor performance could indicate the worsening of
cognitive functions and the early transition from aMCI
to AD. However, longitudinal studies on larger sam-
ples of subjects are needed to confirm and extend our
findings and to clarify the role of kinematic analysis as
a useful tool for the screening of dementia.
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